Valentine M D, Schuberth K C, Kagey-Sobotka A, Graft D F, Kwiterovich K A, Szklo M, Lichtenstein L M
Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21224.
N Engl J Med. 1990 Dec 6;323(23):1601-3. doi: 10.1056/NEJM199012063232305.
The treatment of patients allergic to insect stings with insect-venom injections has been shown to be 97 percent effective in reducing the risk of sting-induced anaphylaxis. However, the frequency of systemic reactions to subsequent stings in unimmunized adults with previous reactions is approximately 60 percent. To determine which factors, in addition to a history of reaction and evidence of venom-specific IgE antibody, predispose patients to future insect-sting reactions, we studied a venom-sensitive group of children who were deemed to be at relatively low risk for severe reactions; 28 percent of them received venom therapy.
We studied 242 children, 2 through 16 years of age, each of whom had had a systemic allergic reaction, affecting only the skin, to an insect sting. Each child had a positive skin-test reaction to one or more of five hymenopteran venoms. Sixty-eight children received immunotherapy with insect venom and 174 did not; about half were randomly assigned to treatment groups, and the rest were assigned on the basis of the patient's (or the parents') choice. The results of accidental stings during four years of observation were evaluated.
In the treated group, 84 stings in 36 patients resulted in one systemic reaction (1.2 percent of stings). In contrast, 196 stings in 86 untreated children resulted in 18 systemic reactions (9.2 percent of stings, P less than 0.001). Sixteen of these 18 reactions were judged to be milder than the patient's reaction to the first sting, 2 were similar in severity, and none were more severe.
These data confirm that immunotherapy with insect venom prevents recurrences of systemic reactions after subsequent insect stings. Because of the surprisingly low rate of reactions among untreated children, we could not identify any characteristics that were predictive of repeat reactions. Since only 9.2 percent of stings in the untreated children led to a systemic reaction and since there was no progression to a more severe reaction, we conclude that venom immunotherapy is unnecessary for most children who are allergic to insect stings.
对于对昆虫叮咬过敏的患者,采用昆虫毒液注射治疗已被证明在降低叮咬诱发过敏反应的风险方面有97%的有效性。然而,既往有反应的未免疫成年人对后续叮咬出现全身反应的频率约为60%。为了确定除了反应史和毒液特异性IgE抗体证据外,还有哪些因素使患者易发生未来的昆虫叮咬反应,我们研究了一组被认为发生严重反应风险相对较低的对毒液敏感的儿童;其中28%接受了毒液治疗。
我们研究了242名2至16岁的儿童,每名儿童都曾因昆虫叮咬出现过仅累及皮肤的全身过敏反应。每名儿童对五种膜翅目昆虫毒液中的一种或多种皮肤试验反应呈阳性。68名儿童接受了昆虫毒液免疫治疗,174名未接受;约一半儿童被随机分配到治疗组,其余儿童根据患者(或父母)的选择进行分配。对四年观察期内意外叮咬的结果进行了评估。
在治疗组中,36名患者的84次叮咬导致1次全身反应(占叮咬次数的1.2%)。相比之下,86名未治疗儿童的196次叮咬导致18次全身反应(占叮咬次数的9.2%,P<0.001)。这18次反应中有16次被判定比患者对首次叮咬的反应轻,2次严重程度相似,没有更严重的。
这些数据证实,昆虫毒液免疫治疗可预防后续昆虫叮咬后全身反应的复发。由于未治疗儿童中反应发生率低得出奇,我们无法确定任何可预测再次反应的特征。由于未治疗儿童中只有9.2%的叮咬导致全身反应,且没有进展为更严重的反应,我们得出结论,对于大多数对昆虫叮咬过敏的儿童,毒液免疫治疗是不必要的。